This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I20 (angina pectoris) | Special Copayment Reduction: V192 (special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Stable angina (I20.8), unstable angina (I20.0), variant angina (Prinzmetal angina, I20.1), chronic coronary syndrome (CCS), ischemic chest pain, coronary heart disease |
| C. Adult onset | Angina occurs mainly in men aged 50 and over, and in women it appears on average 10 years later. With risk factors such as diabetes, smoking and hypertension, it can occur at a younger age. |
| 1. History | 1768: William Heberden first defined angina clinically. 1959: Sones developed coronary angiography. 1977: Gruentzig's first successful PTCA opened the era of intervention. |
| 2. Causes | Coronary artery stenosis due to atherosclerosis (over 80%). Coronary artery spasm (variant), microvascular dysfunction (INOCA). Non-coronary causes: severe anemia, aortic stenosis, hypertrophic cardiomyopathy. |
| 3. Genetics | Genetic contribution to coronary artery disease 40–60%. Multiple genetic variants (GWAS): 9p21.3, SORT1, PCSK9, etc. Familial hypercholesterolemia (FH): LDLR, APOB, PCSK9 variants. Clinical application of polygenic risk scores. |
| 4. General epidemiology | Worldwide prevalence of angina estimated at over about 100 million. About 300,000 per year in Korea. Men > women (middle age), reversed in women after their 60s. Major cardiovascular risk factors: smoking, hypertension, diabetes, dyslipidemia, obesity. |
| 5. Pathophysiology | Coronary artery stenosis due to atherosclerotic plaque → insufficient myocardial oxygen supply → ischemia. Stable: fixed stenosis, ischemia with increased demand. Unstable: plaque rupture and thrombus. Variant: vasospasm. Microvascular dysfunction. |
| 6. Symptoms | Chest pressure, tenderness, tightness (typical), radiating to the left shoulder, arm, jaw and back. Stable: occurs with exertion, relieved by rest and nitroglycerin. Unstable: occurs at rest, longer and more severe. |
| 7. Signs | Sweating, pallor, S3/S4 gallop and mitral regurgitation murmur (during ischemia) during an attack. Physical examination often normal at rest. Xanthomas and corneal arcus (signs of FH). Reduced pulses with accompanying peripheral artery disease. |
| 8. Screening | Screening of high-risk (asymptomatic) groups: ASCVD risk score calculation, coronary artery calcium score (CACS). ECG, exercise stress test. Use of stress echocardiography, nuclear imaging and coronary CT angiography (CCTA) for screening. |
| 9. Diagnosis | ECG (ischemic ST changes), cardiac enzymes (normal in stable angina), exercise ECG, coronary CT angiography (CCTA), coronary angiography (CAG). Unstable: serial troponin measurement essential. |
| 10. Treatment | Antiplatelets (aspirin + clopidogrel), statins, beta-blockers, nitrates, CCBs. Lifestyle modification. Angioplasty (PCI)/stents, coronary artery bypass grafting (CABG). 2024 ESC guidelines: three pillars (lifestyle, medication, revascularization). |
| 11. Prognosis | Stable: annual major adverse cardiovascular events (MACE) 1–3%. Unstable: 30-day death/MI risk 2–10% (depending on TIMI score). Optimal treatment greatly improves prognosis. Diabetes, kidney failure and multivessel disease are poor prognostic factors. |
| 12. Prevention | Primary prevention: smoking cessation, control of blood pressure, blood glucose and lipids, regular exercise, healthy diet. Secondary prevention: continued antiplatelets, statins, ACE inhibitors and beta-blockers. Cardiac rehabilitation programs. |
| 13. References | 2024 ESC Guidelines on Chronic Coronary Syndromes … and 9 other papers |
The history of angina pectoris begins in 1768, when the English physician William Heberden first clinically defined and described "chest pain and a sense of pressure" under the term "angina pectoris" at the Royal College of Physicians in London. Heberden characterized the symptom as intermittent chest discomfort associated with exertion and accurately described the clinical course of the disease in the era before nitroglycerin was introduced. In the late 19th century, nitroglycerin, the key ingredient of the dynamite invented by Alfred Nobel, was paradoxically found to be effective in treating angina, and following amyl nitrite, nitroglycerin became the standard emergency treatment for angina.
In the early 20th century, coronary atherosclerosis was established as the main cause of angina. In 1929 Werner Forssmann of Germany performed the first cardiac catheterization, inserting a catheter into his own arm and advancing it to the right atrium; building on this, in 1959 Mason Sones of the United States developed selective coronary angiography, making it possible to visualize coronary lesions directly. This opened the era of precisely defining the anatomical basis of angina.
The history of interventional cardiology entered a new chapter in 1977, when Andreas Gruentzig of Switzerland performed the first successful percutaneous transluminal coronary angioplasty (PTCA) in a human. Stents were subsequently introduced in 1986, and since the 2000s advances in drug-eluting stents (DES) have markedly reduced restenosis rates. Coronary artery bypass grafting (CABG) has also been performed since the 1960s and became the standard treatment for patients with multivessel disease. The 2024 European Society of Cardiology (ESC) guidelines on chronic coronary syndromes, reflecting the latest evidence, redefined the three pillars of stable angina treatment (lifestyle modification, optimal medical therapy and revascularization).
The most common cause of angina is coronary artery stenosis due to atherosclerosis. When the coronary lumen narrows by 70% or more, adequate blood flow cannot be supplied when myocardial oxygen demand increases (exercise, emotional excitement, hypoxic states), and myocardial ischemia develops. Atherosclerotic plaque consists of oxidized LDL cholesterol, macrophages, foam cells, smooth muscle cells and a fibrous cap, and it progresses over decades.
Unstable angina occurs when rupture or erosion of an atherosclerotic plaque activates platelets and forms a thrombus that partially or completely occludes a coronary artery. If it progresses to complete occlusion, it becomes a myocardial infarction. Variant angina (Prinzmetal angina) is caused by coronary artery spasm and occurs mainly at rest at night or in the early morning. INOCA (ischemia with non-obstructive coronary artery disease) or ANOCA (angina with non-obstructive coronary arteries) refers to ischemia occurring without obvious coronary stenosis, due to microvascular dysfunction or reduced coronary flow reserve (FFR, CFR).
Angina from non-coronary causes includes severe anemia (insufficient oxygen supply), aortic stenosis (increased demand from left ventricular hypertrophy and reduced coronary perfusion pressure), hypertrophic obstructive cardiomyopathy (left ventricular outflow tract obstruction), and hemodynamic instability due to marked bradycardia or tachycardia.
The genetic contribution to coronary artery disease (CAD) is estimated at about 40–60%, and a strong family history is an independent risk factor. Large genome-wide association studies (GWAS) have identified more than 100 loci associated with coronary artery disease. The best known is a polymorphism in the chromosome 9p21.3 region, where the risk allele is reported to increase the risk of CAD by about 30–40%.
Familial hypercholesterolemia (FH) is the representative genetic disease that causes premature coronary artery disease through a monogenic cause. LDLR (LDL receptor) gene variants are the most common (heterozygous FH prevalence 1/200–500), and APOB and PCSK9 gene variants are also causes. In untreated heterozygous FH, LDL cholesterol remains at 190mg/dL or higher, and myocardial infarction occurs dozens of times more often than in the general population.
A polygenic risk score (PRS) is a tool that quantifies an individual's genetic risk of coronary artery disease by combining dozens to hundreds of CAD-related genetic variants, and its predictive power improves when combined with clinical risk factor scores (Framingham score, ASCVD score). Recent PCSK9 inhibitors (evolocumab, alirocumab, etc.) are therapies that block the function of the PCSK9 gene, increasing LDL receptor recycling and dramatically lowering LDL cholesterol; they are used in patients with FH and high-risk CAD.
Angina is one of the most common cardiovascular diseases worldwide. The number of people with stable angina worldwide is estimated at over about 100 million, and deaths from coronary artery disease overall (including acute myocardial infarction) exceed 9 million per year. In Korea, more than about 300,000 patients are diagnosed with angina each year, and incidence is rising due to population aging and the increasing prevalence of obesity, diabetes and hypertension.
Epidemiologically, men develop coronary artery disease about 10 years earlier than women, and after menopause incidence rises sharply in women as the protective effect of estrogen is lost. Major modifiable risk factors include smoking, hypertension, diabetes, dyslipidemia (especially elevated LDL-C), obesity, physical inactivity and psychosocial stress. Non-modifiable factors include age, male sex and family history. In low- and middle-income countries, mortality from coronary artery disease is rising, mainly due to population aging and Westernized lifestyles.
The mechanism of stable angina is a supply-demand imbalance in which blood supply becomes insufficient when myocardial oxygen demand increases, due to fixed stenosis from coronary atherosclerotic plaque. With stenosis of 70% or more of the coronary lumen, sufficient blood flow is maintained at rest, but when heart rate and contractility increase with exercise or emotional excitement, myocardial oxygen consumption rises and ischemia develops. When ischemia occurs, cardiomyocytes switch to anaerobic metabolism, lactate accumulates, and pain mediators such as adenosine and bradykinin are released, causing chest pain.
The mechanism of unstable angina is platelet aggregation and thrombus formation due to sudden rupture or erosion of an atherosclerotic plaque. Unstable plaques, characterized by a thin fibrous cap and a large lipid core, rupture due to shear stress, inflammation, endogenous vasoconstriction and other factors. When a partial thrombus intermittently blocks coronary blood flow, angina occurs even at rest or with minimal exertion. In variant angina, focal or diffuse vasospasm occurs in normal or mildly stenosed coronary arteries, and endothelial dysfunction and autonomic nervous system disturbance are presumed to be the causes of the spasm.
Typical angina symptoms are described as chest pressure, tightness, heaviness or burning and may be indicated by the Levine sign, placing a clenched fist over the sternum. The pain begins centrally in the anterior chest (retrosternal) and may radiate toward the left shoulder, arm (especially the inner side), neck, jaw and back. Stable angina is triggered by specific precipitating factors (walking, climbing stairs, cold air, meals, emotional excitement) and resolves within 2–5 minutes of rest or sublingual nitroglycerin.
Unstable angina presents as one of ① new-onset severe angina, ② angina at rest or ③ progressively worsening angina (crescendo angina). Pain that lasts longer (20 minutes or more), is more intense and is not adequately relieved by rest and nitroglycerin strongly suggests unstable angina. Atypical symptoms such as dyspnea, nausea, sweating, fatigue and indigestion may appear, and these are more common in women, older adults and diabetic patients.
During an angina attack, physical examination may show sweating, pallor, tachycardia and elevated (or lowered) blood pressure. Changes in heart rate and blood pressure result from autonomic activation. On auscultation, a mitral regurgitation murmur (holosystolic murmur) due to ischemia-induced papillary muscle dysfunction may appear transiently, and an S3 or S4 gallop rhythm may be heard with ventricular dysfunction. Most of these findings disappear once the attack resolves.
Because physical examination at rest is mostly normal, the diagnosis of angina relies heavily on history taking (character of symptoms, precipitating and relieving factors). With familial hypercholesterolemia, tendon xanthomas (tendinous xanthoma, especially of the Achilles tendon and back of the hand), skin xanthomas (xanthelasma) and corneal arcus may be found on physical examination. With accompanying peripheral artery disease, reduced dorsalis pedis pulses, abnormal skin color and temperature, and non-healing wounds are observed.
Screening for angina in asymptomatic high-risk adults begins with cardiovascular risk stratification. The 10-year cardiovascular risk is calculated using the ASCVD risk score (American College of Cardiology/American Heart Association Pooled Cohort Equations) or SCORE2 (Europe), and in intermediate-risk patients (10-year risk 7.5–20%) the coronary artery calcium score (CACS) is measured to reclassify risk. If CACS is 0, no further testing is needed; if it is 100 or higher, the patient is high risk and aggressive treatment is started.
In symptomatic patients, a resting ECG and an exercise ECG are used as first-line screening tests. If ischemic findings (ST depression ≥1mm, provoked chest pain, drop in blood pressure) are seen on exercise testing, further imaging follows. In symptomatic patients unable to exercise, pharmacologic stress echocardiography (dobutamine stress echo) or nuclear imaging (SPECT/PET myocardial perfusion scan) is used. For noninvasive anatomical screening, coronary CT angiography (CCTA) is excellent for accurately assessing the presence and degree of coronary stenosis.
The diagnosis of angina is based on a characteristic history (nature of the chest pain, precipitating and relieving factors, duration). The resting ECG may be normal between attacks but can show ischemic findings such as ST depression, T-wave inversion, left bundle branch block and Q waves. ST-segment changes on the ECG during an attack are the most important finding.
In diagnosing unstable angina, serial measurement of high-sensitivity troponin (high-sensitivity troponin I or T) is essential. Values at 0 hours and 1 hour (or 2 hours) are compared to confirm myocardial injury early. Without troponin elevation it is classified as unstable angina, and with elevation as NSTEMI.
To evaluate coronary anatomy, coronary CT angiography (CCTA) noninvasively assesses the presence of coronary stenosis and plaque characteristics. Invasive coronary angiography (ICA) is invasive but evaluates coronary anatomy most accurately and allows interventional treatment to be performed at the same time. For functional assessment of ischemia, measurement of fractional flow reserve (FFR) or the instantaneous wave-free ratio (iFR) is used to decide whether an interventional procedure is needed.
The 2024 ESC guidelines on chronic coronary syndromes set out the three pillars of treatment as ① a healthy lifestyle (smoking cessation, adequate exercise, Mediterranean diet), ② optimal medical therapy (drugs to prevent cardiovascular events + drugs to control ischemic symptoms) and ③ revascularization (when needed).
Medical therapy: antiplatelet agents (aspirin 75–100mg/day; add a P2Y12 inhibitor when unstable/high risk), high-intensity statins (atorvastatin 40–80mg or rosuvastatin 20–40mg), beta-blockers (stable angina: symptom control; improved prognosis with reduced LVEF), long-acting nitrates (symptom control), ACE inhibitors or ARBs (with reduced LVEF, diabetes, hypertension or nephropathy). For symptom control, non-dihydropyridine CCBs (amlodipine), ivabradine and ranolazine are also used. PCSK9 inhibitors are added when the LDL-C target is not achieved with statins.
Revascularization: percutaneous coronary intervention (PCI)/stenting is preferred for single- or two-vessel disease and acute coronary syndrome (ACS, including unstable angina). Coronary artery bypass grafting (CABG) shows better long-term outcomes than PCI for left main disease, three-vessel disease, complex multivessel disease and multivessel disease with diabetes. In unstable angina, the need for an early invasive strategy (coronary angiography within 2–72 hours) is decided by risk stratification (TIMI, GRACE scores).
The annual rate of major adverse cardiovascular events (death, myocardial infarction: MACE) in stable angina is about 1–3% under optimal medical therapy. Prognosis varies with the burden of risk factors (diabetes, kidney failure, multivessel disease, left ventricular dysfunction, LVEF <50%). Unstable angina is one form of acute coronary syndrome, with a 30-day risk of death or myocardial infarction reaching 2–10% depending on the TIMI risk score. Prognosis improves with early invasive treatment and dual antiplatelet therapy. Variant angina has a good prognosis with relief of spasm, but acute myocardial infarction from repeated coronary spasm or sudden death from ventricular arrhythmia rarely occurs.
Primary prevention: the key elements are smoking cessation (halves cardiovascular risk), regular aerobic exercise (at least 150 minutes per week of moderate intensity), a Mediterranean or DASH diet, maintaining a normal weight (BMI 18.5–25kg/m²), blood pressure control (target <130/80mmHg), glycemic control (HbA1c <7% or an individualized target) and LDL-C reduction (general risk <100mg/dL, high risk <70mg/dL, very high risk <55mg/dL). Managing psychosocial stress and treating sleep disorders are also important.
Secondary prevention: In patients with established coronary artery disease, continued use of antiplatelet agents (aspirin), high-intensity statins, ACE inhibitors/ARBs and beta-blockers (after myocardial infarction) significantly reduces recurrent cardiovascular events. After PCI or CABG, dual antiplatelet therapy (DAPT) is maintained for an appropriate period. Cardiac rehabilitation programs have proven benefits in improving exercise capacity and quality of life and reducing readmission rates.
Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines on Chronic Coronary Syndromes. European Heart Journal. 2024;45(36):3415-3537. DOI: 10.1093/eurheartj/ehae177. PMID: 39210710.
Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2020;41(3):407-477. DOI: 10.1093/eurheartj/ehz425. PMID: 31504439.
Libby P, Pasterkamp G, Crea F, Jang IK. Reassessing the mechanisms of acute coronary syndromes. Circulation Research. 2019;124(1):150-160. DOI: 10.1161/CIRCRESAHA.118.311098. PMID: 30605420.
Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal. 2013;34(38):2949-3003. DOI: 10.1093/eurheartj/eht296. PMID: 23996286.
Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. New England Journal of Medicine. 2020;382(15):1395-1407. DOI: 10.1056/NEJMoa1915922. PMID: 32227755.
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine. 2017;376(18):1713-1722. DOI: 10.1056/NEJMoa1615664. PMID: 28304224.
Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease. Journal of the American College of Cardiology. 2012;60(24):e44-e164. DOI: 10.1016/j.jacc.2012.07.013. PMID: 23182125.
Heberden W. Some account of a disorder of the breast. Medical Transactions of the Royal College of Physicians of London. 1772;2:59-67.
Park DW, Clare RM, Schulte PJ, et al. Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. JAMA. 2014;312(19):2019-2027. DOI: 10.1001/jama.2014.15095. PMID: 25399277.
Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. New England Journal of Medicine. 2007;356(15):1503-1516. DOI: 10.1056/NEJMoa070829. PMID: 17387127.